197 related articles for article (PubMed ID: 32634285)
21. The impaired bone anabolic effect of PTH in the absence of endogenous FGF2 is partially due to reduced ATF4 expression.
Fei Y; Xiao L; Hurley MM
Biochem Biophys Res Commun; 2011 Aug; 412(1):160-4. PubMed ID: 21806973
[TBL] [Abstract][Full Text] [Related]
22. Lipoprotein receptor-related protein 6 is required for parathyroid hormone-induced Sost suppression.
Li C; Wang W; Xie L; Luo X; Cao X; Wan M
Ann N Y Acad Sci; 2016 Jan; 1364(1):62-73. PubMed ID: 25847683
[TBL] [Abstract][Full Text] [Related]
23. Normal epidermal growth factor receptor signaling is dispensable for bone anabolic effects of parathyroid hormone.
Schneider MR; Dahlhoff M; Andrukhova O; Grill J; Glösmann M; Schüler C; Weber K; Wolf E; Erben RG
Bone; 2012 Jan; 50(1):237-44. PubMed ID: 22056328
[TBL] [Abstract][Full Text] [Related]
24. TGF-beta type II receptor phosphorylates PTH receptor to integrate bone remodelling signalling.
Qiu T; Wu X; Zhang F; Clemens TL; Wan M; Cao X
Nat Cell Biol; 2010 Mar; 12(3):224-34. PubMed ID: 20139972
[TBL] [Abstract][Full Text] [Related]
25. Control of Bone Anabolism in Response to Mechanical Loading and PTH by Distinct Mechanisms Downstream of the PTH Receptor.
Delgado-Calle J; Tu X; Pacheco-Costa R; McAndrews K; Edwards R; Pellegrini GG; Kuhlenschmidt K; Olivos N; Robling A; Peacock M; Plotkin LI; Bellido T
J Bone Miner Res; 2017 Mar; 32(3):522-535. PubMed ID: 27704638
[TBL] [Abstract][Full Text] [Related]
26. The roles of parathyroid hormone in bone remodeling: prospects for novel therapeutics.
Lombardi G; Di Somma C; Rubino M; Faggiano A; Vuolo L; Guerra E; Contaldi P; Savastano S; Colao A
J Endocrinol Invest; 2011 Jul; 34(7 Suppl):18-22. PubMed ID: 21985975
[TBL] [Abstract][Full Text] [Related]
27. Pleckstrin homology (PH) domain and Leucine Rich Repeat Phosphatase 1 (Phlpp1) Suppresses Parathyroid Hormone Receptor 1 (Pth1r) Expression and Signaling During Bone Growth.
Weaver SR; Taylor EL; Zars EL; Arnold KM; Bradley EW; Westendorf JJ
J Bone Miner Res; 2021 May; 36(5):986-999. PubMed ID: 33434347
[TBL] [Abstract][Full Text] [Related]
28. Targeted overexpression of Dkk1 in osteoblasts reduces bone mass but does not impair the anabolic response to intermittent PTH treatment in mice.
Yao GQ; Wu JJ; Troiano N; Insogna K
J Bone Miner Metab; 2011 Mar; 29(2):141-8. PubMed ID: 20602130
[TBL] [Abstract][Full Text] [Related]
29. Parathyroid Hormone Induces Bone Cell Motility and Loss of Mature Osteocyte Phenotype through L-Calcium Channel Dependent and Independent Mechanisms.
Prideaux M; Dallas SL; Zhao N; Johnsrud ED; Veno PA; Guo D; Mishina Y; Harris SE; Bonewald LF
PLoS One; 2015; 10(5):e0125731. PubMed ID: 25942444
[TBL] [Abstract][Full Text] [Related]
30. Disruption of LRP6 in osteoblasts blunts the bone anabolic activity of PTH.
Li C; Xing Q; Yu B; Xie H; Wang W; Shi C; Crane JL; Cao X; Wan M
J Bone Miner Res; 2013 Oct; 28(10):2094-108. PubMed ID: 23609180
[TBL] [Abstract][Full Text] [Related]
31. Identification of a novel integrin alphavbeta3 binding site in CCN1 (CYR61) critical for pro-angiogenic activities in vascular endothelial cells.
Chen N; Leu SJ; Todorovic V; Lam SC; Lau LF
J Biol Chem; 2004 Oct; 279(42):44166-76. PubMed ID: 15308622
[TBL] [Abstract][Full Text] [Related]
32. Anabolic effects of PTH in cyclooxygenase-2 knockout osteoblasts in vitro.
Choudhary S; Huang H; Raisz L; Pilbeam C
Biochem Biophys Res Commun; 2008 Aug; 372(4):536-41. PubMed ID: 18501188
[TBL] [Abstract][Full Text] [Related]
33. CCN1 induces hepatic ductular reaction through integrin αvβ₅-mediated activation of NF-κB.
Kim KH; Chen CC; Alpini G; Lau LF
J Clin Invest; 2015 May; 125(5):1886-900. PubMed ID: 25822023
[TBL] [Abstract][Full Text] [Related]
34. Parathyroid hormone 1 receptor signaling mediates breast cancer metastasis to bone in mice.
Swami S; Zhu H; Nisco A; Kimura T; Kim MJ; Nair V; Wu JY
JCI Insight; 2023 Mar; 8(5):. PubMed ID: 36692956
[TBL] [Abstract][Full Text] [Related]
35. Decreased oxidative stress and greater bone anabolism in the aged, when compared to the young, murine skeleton with parathyroid hormone administration.
Jilka RL; Almeida M; Ambrogini E; Han L; Roberson PK; Weinstein RS; Manolagas SC
Aging Cell; 2010 Oct; 9(5):851-67. PubMed ID: 20698835
[TBL] [Abstract][Full Text] [Related]
36. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment.
Sawakami K; Robling AG; Ai M; Pitner ND; Liu D; Warden SJ; Li J; Maye P; Rowe DW; Duncan RL; Warman ML; Turner CH
J Biol Chem; 2006 Aug; 281(33):23698-711. PubMed ID: 16790443
[TBL] [Abstract][Full Text] [Related]
37. Over-expression of TIMP-1 in osteoblasts increases the anabolic response to PTH.
Merciris D; Schiltz C; Legoupil N; Marty-Morieux C; de Vernejoul MC; Geoffroy V
Bone; 2007 Jan; 40(1):75-83. PubMed ID: 16949899
[TBL] [Abstract][Full Text] [Related]
38. Conditionally immortalized murine osteoblasts lacking the type 1 PTH/PTHrP receptor.
Divieti P; Lanske B; Kronenberg HM; Bringhurst FR
J Bone Miner Res; 1998 Dec; 13(12):1835-45. PubMed ID: 9844101
[TBL] [Abstract][Full Text] [Related]
39. Role of paraoxonase-1 in bone anabolic effects of parathyroid hormone in hyperlipidemic mice.
Lu J; Cheng H; Atti E; Shih DM; Demer LL; Tintut Y
Biochem Biophys Res Commun; 2013 Feb; 431(1):19-24. PubMed ID: 23291186
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms underlying catabolic and anabolic functions of parathyroid hormone on bone by combination of culture systems of mouse cells.
Shinoda Y; Kawaguchi H; Higashikawa A; Hirata M; Miura T; Saito T; Nakamura K; Chung UI; Ogata N
J Cell Biochem; 2010 Mar; 109(4):755-63. PubMed ID: 20058231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
